Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Piramal cuts...

    Piramal cuts short-term borrowings, reduces dependence on CPs as NBFC crisis lingers

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-12T09:15:42+05:30  |  Updated On 16 Aug 2021 11:20 AM IST

    Piramal Enterprises chairman Ajay Piramal in his address to the shareholders in the FY19 annual report said the company continues to build resilience by further strengthening its liability and asset side.


    Mumbai: Default by a large financial services player on its debt instruments has forced Piramal Enterprises to shift its borrowing mix to longer-term funding sources, and significantly reduce dependence on commercial papers, a top company official has said.


    Read Also: Ressurecting Sun Pharma: Shanghvi committed to pharma business; surrenders NBFC licenc


    Piramal Enterprises chairman Ajay Piramal in his address to the shareholders in the FY19 annual report said the company continues to build resilience by further strengthening its liability and asset side.


    "In September 2018, the default by a large financial services company on its debt instruments resulted in a sector-wide liquidity tightening. As a result, banks and mutual funds resorted to a cautious approach towards financing NBFCs," he said without naming IL&FS which went belly up in that month. This, he said forced them to look for longer-term funds and not short terms sources like CPs or CDs.


    Recognising the negative sentiment on NBFCs, the company has shifted its borrowing mix towards longer-term sources of funds and significantly reduced the dependence on CPs from Rs 18,000 crore in September 2018 to Rs 8,900 crore in March 2019, he said.


    It also raised Rs 16,500 crore, which is nearly 30 percent of its loan book, via NCDs and bank loans between September 2018 and March 2019.


    "We continue to diversify our loan book and increase its granularity, as we aim to lower the overall risk profile. Wholesale real estate exposure has come down from 83 percent in March 2015 to 63 percent in March 2019, excluding hospitality and lease rental discounting," he said.


    Noting that several NBFCs saw their loan books stagnate or shrink in the second half of FY19, due to funding constraints, he said, "despite this, their loan book grew 34 percent to Rs 56,624 crore and fresh disbursals of Rs 29,762 crore during the year, of which Rs 11,241 crore were disbursed in H2. In addition, we received re-payments worth Rs 16,658 crore during the year, nearly half of which in H2."


    The company's financial services business delivered good returns of nearly 19 percent for FY19, despite the continuous de-risking of the loan book and fund raising in the previous year, he said.


    On the performance of the pharma business, he said their differentiated business model has delivered sustained revenue growth despite pricing pressures and regulatory concerns that impacted the industry.


    Read Also: Sun Pharma Whole Time Director Sudhir Valia steps down from executive role


    During the year, its domestic pharma business grew 11 percent to Rs 4,786 crore, while global pharma business crossed Rs 1,000 crore in operating profit with a margin of 23 percent.

    Ajay PiramaldebenturesFY19NBFCNCDnon banking financial associationnon-convertible debenturespharmaPiramalPiramal enterprises
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok